According to VentureBeat, HoloMD just closed a $1.6 million first tranche of its $3 million seed round and will host a virtual investor briefing on November 11, 2025 at 12:00 p.m. ET. The funding will accelerate development of Dr. Holo, their AI-powered mental health platform that supports psychiatrists and patients between visits. In just 15 months, the company has moved from concept to live revenue and proven its Remote Therapeutic Monitoring reimbursement model with multiple commercial payers. Founder Bruce A. Kehr, MD leads the company, which currently has seven provisional patents and one utility patent pending. Interested investors can RSVP to Dominic Fabrizio for the 45-minute presentation.
Sponsored content — provided for informational and promotional purposes.
The reimbursement angle changes everything
Here’s what makes HoloMD interesting – they’re not just another mental health app. They’ve built their entire platform around Remote Therapeutic Monitoring (RTM) reimbursement codes. Basically, they’re turning what used to be unpaid work between patient visits into billable services. That’s huge for psychiatrists who’ve been burning out from uncompensated after-hours work.
And they’re not just claiming it works – they say they’ve already validated RTM billing across multiple commercial payers. In today’s crowded mental health tech space, having a clear revenue model from day one is pretty unusual. Most startups focus on user growth first and figure out monetization later.
Human-supervised AI is the right approach
I’m skeptical of fully automated mental health AI – there’s just too much that can go wrong. But HoloMD seems to get this. Their Dr. Holo platform has licensed clinicians reviewing every interaction. That human oversight layer is crucial for safety and accuracy in psychiatry, where context and nuance matter tremendously.
So they’re essentially creating a hybrid model: AI handles the daily check-ins and data collection, while humans provide the clinical judgment. This could actually scale better than pure telehealth, since one clinician could potentially supervise dozens of AI-patient relationships simultaneously.
Where this fits in the mental health tech wars
The mental health tech space is absolutely packed right now. You’ve got everything from pure play teletherapy to meditation apps trying to become clinical tools. HoloMD’s differentiator is that they’re not replacing psychiatrists – they’re augmenting them.
That’s smart positioning. Instead of competing with providers, they’re giving them tools to be more efficient and profitable. And by focusing specifically on psychiatry rather than general mental wellness, they can build deeper expertise and better reimbursement pathways. The question is whether practices will actually adopt this alongside their existing workflows, or if it becomes just another piece of software they ignore.
If HoloMD can prove their model improves outcomes while generating real revenue for providers, they might have found that rare sweet spot in healthcare tech. But they’ll need to show more than just early deployments – they’ll need to demonstrate sustained engagement and clinical impact at scale. The November 11 investor call should give us more clues about whether they’re delivering on that promise.
